NEW YORK, May 5 - Phase-1 Molecular Toxicology said today that it is providing toxicogenomics services for the National Cancer Institute.
Specifically, the company said it will analyze the toxicity of cancer treatments in comparison to the mechanism of antitumor action.
Phase-1 will receive animal tissues from several contract laboratories performing preclinical safety studies for the NCI and will evaluate the tissues for treatment-related gene expression effects.
According to Joseph Tomaszewski, chief of the toxicology and pharmacology branch at NCI, Phase-1 was chosen as NCI's service partner because "they have toxchips for the relevant species in which we perform our toxicity studies."